AZD7624

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555289

CAS#: 1095004-78-6

Description: AZD-7624 a potent, selective, inhaled p38α MAPK inhibitor for the treatment of chronic obstructive pulmonary disease. AZD7624 demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure.


Chemical Structure

img
AZD7624
CAS# 1095004-78-6

Theoretical Analysis

MedKoo Cat#: 555289
Name: AZD7624
CAS#: 1095004-78-6
Chemical Formula: C27H30FN5O3
Exact Mass: 491.23
Molecular Weight: 491.567
Elemental Analysis: C, 65.97; H, 6.15; F, 3.86; N, 14.25; O, 9.76

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AZD-7624; AZD 7624; AZD7624;

IUPAC/Chemical Name: N-cyclopropyl-3-fluoro-4-methyl-5-(3-((1-(2-(2-(methylamino)ethoxy)phenyl)cyclopropyl)amino)-2-oxopyrazin-1(2H)-yl)benzamide

InChi Key: NNKPHNTWNILINE-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34)

SMILES Code: O=C(NC1CC1)C2=CC(N3C(C(NC4(C5=CC=CC=C5OCCNC)CC4)=NC=C3)=O)=C(C)C(F)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info: The p38 protein kinases, in particular p38α and p38β, regulate the production of multiple inflammatory mediators. Consequentially, considerable effort has been focused on trying to develop p38 inhibitors for the treatment of inflammatory diseases

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 491.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Higham A, Karur P, Jackson N, Cunoosamy DM, Jansson P, Singh D. Differential
anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD
pulmonary cells. Int J Chron Obstruct Pulmon Dis. 2018 Apr 19;13:1279-1288. doi:
10.2147/COPD.S159936. eCollection 2018. PubMed PMID: 29719383; PubMed Central
PMCID: PMC5914546.

2: Patel NR, Cunoosamy DM, Fagerås M, Taib Z, Asimus S, Hegelund-Myrbäck T,
Lundin S, Pardali K, Kurian N, Ersdal E, Kristensson C, Korsback K, Palmér R,
Brown MN, Greenaway S, Siew L, Clarke GW, Rennard SI, Make BJ, Wise RA, Jansson
P. The development of AZD7624 for prevention of exacerbations in COPD: a
randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2018 Mar
27;13:1009-1019. doi: 10.2147/COPD.S150576. eCollection 2018. PubMed PMID:
29628759; PubMed Central PMCID: PMC5877500.

3: Pehrson R, Hegelund-Myrbäck T, Cunoosamy D, Asimus S, Jansson P, Patel N,
Borde A, Lundin S. AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung
Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure. J Pharmacol Exp
Ther. 2018 Jun;365(3):567-572. doi: 10.1124/jpet.117.246132. Epub 2018 Mar 16.
PubMed PMID: 29549158.

4: Gross N. The COPD Pipeline XXXII. Chronic Obstr Pulm Dis. 2016 Jul
14;3(3):688-692. doi: 10.15326/jcopdf.3.3.2016.0150. PubMed PMID: 28848893;
PubMed Central PMCID: PMC5556764.

5: Widdifield CM, Nilsson Lill SO, Broo A, Lindkvist M, Pettersen A, Svensk
Ankarberg A, Aldred P, Schantz S, Emsley L. Does Z' equal 1 or 2? Enhanced powder
NMR crystallography verification of a disordered room temperature crystal
structure of a p38 inhibitor for chronic obstructive pulmonary disease. Phys Chem
Chem Phys. 2017 Jun 28;19(25):16650-16661. doi: 10.1039/c7cp02349a. PubMed PMID:
28621371.